TY - JOUR
T1 - Characteristics of adult patients newly diagnosed with Crohn’s disease
T2 - interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD)
AU - Matsuoka, Katsuyoshi
AU - Fujii, Toshimitsu
AU - Okamoto, Ryuichi
AU - Yamada, Akihiro
AU - Kunisaki, Reiko
AU - Matsuura, Minoru
AU - Watanabe, Kenji
AU - Shiga, Hisashi
AU - Takatsu, Noritaka
AU - Bamba, Shigeki
AU - Mikami, Yohei
AU - Yamamoto, Takayuki
AU - Shimoyama, Takahiro
AU - Motoya, Satoshi
AU - Torisu, Takehiro
AU - Kobayashi, Taku
AU - Ohmiya, Naoki
AU - Saruta, Masayuki
AU - Matsuda, Koichiro
AU - Matsumoto, Takayuki
AU - Nakase, Hiroshi
AU - Maemoto, Atsuo
AU - Shinzaki, Shinichiro
AU - Murata, Yoko
AU - Yoshigoe, Shinichi
AU - Sasaki, Ayako
AU - Yajima, Tsutomu
AU - Hisamatsu, Tadakazu
N1 - Funding Information:
KM received research grant from Janssen Pharmaceutical K.K.; received scholarship grants from AbbVie, EA, Mitsubishi Tanabe, Mochida, Nippon Kayaku; received honoraria from AbbVie, EA, Janssen Pharmaceutical K.K., Mitsubishi Tanabe, Mochida, Pfizer, Takeda. TF received honorarium and research grants from Janssen Pharmaceutical K.K. SS received research grant from Sekisui Medical; received honoraria from Tanabe Mitsubishi, Janssen. RO received research grant from Mitsubishi Tanabe; received scholarship grant from Zeria, Mochida, Takeda. AY received research grants from AbbVie, EA, Mitsubishi Tanabe, Mochida. YM, TY, KM received honorarium from Janssen. MM received personal honorarium from Janssen Pharmaceutical K.K. KW received research grants from EA Pharma, EP-CRSU Co., Ltd., Takeda; received scholarship grants from AbbVie, EA, Mitsubishi Tanabe, JIMRO, Nippon Kayaku; received honoraria from AbbVie, EA Pharma, Kissei, Pfizer, Takeda, MTPC, Kyorin, Mochida; endowed chair from AbbVie, EA Pharma, Zeria, Kyorin, MTPC, JIMRO, Otsuka Pharmaceutical Factory, Asahi Kasei Medical Co., Ltd, Mochida. SB received honorarium from Janssen Pharmaceutical K.K. SM received honoraria from Takeda, Mitsubishi Tanabe, Janssen; received research grants from Janssen, Pfizer, Eli Lilly, EA Pharma, Takeda, Astrazeneca. TT received research grant from Mitsubishi Tanabe, AbbVie. TK received honoraria from AbbVie, Takeda, Tanabe Mitsubishi, Pfizer, Janssen; received research grants from Nippon Kayaku, Pfizer, AbbVie, Activaid, Takeda, Alfresa, Ferring, JMDC, Janssen, Gilead Sciences, Bristol-Myers Squibb, Eli Lilly Japan, Mochida; received scholarship grants from Tanabe Mitsubishi, Zeria, Nippon Kayaku; endowed chair from Otsuka Holdings, JIMRO, EA, AbbVie, Zeria, Kyorin, Mochida. NO received commissioned/joint research grants from AbbVie, Daiichi Sankyo, Eli Lilly, EA, University of Miyazaki, Mylan EPD, Nippon Kayaku, Ajinomoto, Okawa foundation for information and telecommunications, Suzuken Memorial Foundation, Japanese society of gastroenterology, Japanese gastroenterological association; received scholarship grants from Bristol-Myers Squibb, AbbVie, Takeda, Eli Lilly, Tanabe Mitsubishi, Nippon Kayaku. MS received honoraria from AbbVie, Janssen, Tanabe Mitsubishi, Mochida, Zeria, Takeda, Kissei, Pfizer; received fees for promotional materials from EA Pharma; received research grants from EP-CRSU; received scholarship donations from EA Pharma, Kissei, Zeria, Mochida, Otsuka, Takeda. TM received honoraria from EA Pharma, Janssen, Takeda, Tanabe Mitsubishi, Sekisui Medical, AbbVie; received scholarship grants from Tanabe Mitsubishi, Nippon Kayaku. HN received honoraria from AbbVie, Tanabe Mitsubishi, Janssen, Takeda, Pfizer, Mylan EPD; received grants for commissioned/joint research from HOYA Pentax Medical, AbbVie, Tanabe Mitsubishi, Mochida, AYUMI Pharmaceutical Corporation; received scholarship grants from AbbVie, Otsuka, EA Pharma, Taiho, Nippon Kayaku, Tanabe Mitsubishi, Takeda. SS received honoraria from Tanabe Mitsubishi, Janssen; received research grant from Sekisui Medical. TH received honoraria from Mitsubishi Tanabe, Pfizer, AbbVie GK, Janssen Pharmaceutical K.K., EA Pharma, Takeda; received research grants from Alfresa and Ajinomoto; received scholarship grants from Mitsubishi Tanabe, AbbVie GK, EA Pharma, Takeda, JIMRO, Mochida, Daiichi Sankyo, Pfizer. YM, SY, AS and TY are employees of Janssen Pharmaceutical K.K. No conflicts of interest declared for RK, HS, NT, Yohei Mikami (YM), Takayuki Yamamoto (TY), TS, AM.
Funding Information:
The authors would like to thank the Japanese Society for Inflammatory Bowel Disease for support to the study. The authors also thank the collaborators to enroll patients. The iCREST-CD Study Group consists of the following members excluding the authors are listed in the Supplemental material 1. Mizuki Amano and Tomoko Takano (Janssen Pharmaceutical K.K., Tokyo, Japan) provided administrative, technical, or material support for this study. Hiroki Nakane (EPS Corp.) for performing the statistical analysis. Writing assistance and editorial support for this manuscript was provided by Nigar Malik, B. Pharm (SIRO Clinpharm Pvt Ltd, India). Statistical analysis support and medical writing assistance were both funded by Janssen Pharmaceutical K.K. The manuscript, including related data, figures, and tables, has not been previously published and the manuscript is not under consideration elsewhere.
Funding Information:
The authors would like to thank the Japanese Society for Inflammatory Bowel Disease for support to the study. The authors also thank the collaborators to enroll patients. The iCREST-CD Study Group consists of the following members excluding the authors are listed in the Supplemental material 1. Mizuki Amano and Tomoko Takano (Janssen Pharmaceutical K.K., Tokyo, Japan) provided administrative, technical, or material support for this study. Hiroki Nakane (EPS Corp.) for performing the statistical analysis. Writing assistance and editorial support for this manuscript was provided by Nigar Malik, B. Pharm (SIRO Clinpharm Pvt Ltd, India). Statistical analysis support and medical writing assistance were both funded by Janssen Pharmaceutical K.K. The manuscript, including related data, figures, and tables, has not been previously published and the manuscript is not under consideration elsewhere.
Publisher Copyright:
© 2022, Japanese Society of Gastroenterology.
PY - 2022/11
Y1 - 2022/11
N2 - Background: The Inception Cohort Registry Study of Patients with Crohn’s Disease aimed to clarify clinical characteristics and disease course of newly diagnosed Crohn’s disease patients in Japan throughout a 4-year period. Results from an interim analysis of the largest nation-wide registry study that covers approximately 1% of Crohn’s disease patient population in Japan are reported. Methods: This prospective, observational registry study was conducted at 19 tertiary centers in Japan. Patients newly diagnosed with Crohn’s disease after June 2016 (age ≥ 16 years at informed consent) were enrolled between December 17, 2018 and June 30, 2020. Patient demographics, diagnostic procedures and categories, disease location and lesion behavior (Montreal classification) at the time of diagnosis were recorded. Results: Of 673 patients enrolled, 672 (99.9%) were analyzed (458: men, 214: women), male-to-female ratio: 2.1, median age at diagnosis 25 (range 13–86) years; peak age of disease diagnosis: 20–24 years. Most common disease location was L3 (ileocolonic; 60.1%). Non-stricturing, non-penetrating (B1) disease was most common behavior (62.8%); 48.9% reported perianal lesions. Notably, age-wise analysis revealed disease phenotypes varied between patients aged < 40 and ≥ 40 years in terms of male-to-female ratio (2.5/1.3)/disease location (L3: 66.3%/37.0%)/disease behavior (B1: 66.4%/50.0%)/perianal lesion: (55.7%/20.5%) at Crohn’s disease diagnosis, respectively. Conclusions: Interim analysis of this nation-wide Inception Cohort Registry Study of Patients with Crohn’s Disease revealed the demographics and disease characteristics of newly diagnosed Crohn’s disease patients in Japan and demonstrated that disease phenotype varied between patients aged < 40 and ≥ 40 years, serving as important information for management of individual patients.
AB - Background: The Inception Cohort Registry Study of Patients with Crohn’s Disease aimed to clarify clinical characteristics and disease course of newly diagnosed Crohn’s disease patients in Japan throughout a 4-year period. Results from an interim analysis of the largest nation-wide registry study that covers approximately 1% of Crohn’s disease patient population in Japan are reported. Methods: This prospective, observational registry study was conducted at 19 tertiary centers in Japan. Patients newly diagnosed with Crohn’s disease after June 2016 (age ≥ 16 years at informed consent) were enrolled between December 17, 2018 and June 30, 2020. Patient demographics, diagnostic procedures and categories, disease location and lesion behavior (Montreal classification) at the time of diagnosis were recorded. Results: Of 673 patients enrolled, 672 (99.9%) were analyzed (458: men, 214: women), male-to-female ratio: 2.1, median age at diagnosis 25 (range 13–86) years; peak age of disease diagnosis: 20–24 years. Most common disease location was L3 (ileocolonic; 60.1%). Non-stricturing, non-penetrating (B1) disease was most common behavior (62.8%); 48.9% reported perianal lesions. Notably, age-wise analysis revealed disease phenotypes varied between patients aged < 40 and ≥ 40 years in terms of male-to-female ratio (2.5/1.3)/disease location (L3: 66.3%/37.0%)/disease behavior (B1: 66.4%/50.0%)/perianal lesion: (55.7%/20.5%) at Crohn’s disease diagnosis, respectively. Conclusions: Interim analysis of this nation-wide Inception Cohort Registry Study of Patients with Crohn’s Disease revealed the demographics and disease characteristics of newly diagnosed Crohn’s disease patients in Japan and demonstrated that disease phenotype varied between patients aged < 40 and ≥ 40 years, serving as important information for management of individual patients.
UR - http://www.scopus.com/inward/record.url?scp=85135471663&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135471663&partnerID=8YFLogxK
U2 - 10.1007/s00535-022-01907-2
DO - 10.1007/s00535-022-01907-2
M3 - Article
C2 - 35930087
AN - SCOPUS:85135471663
VL - 57
SP - 867
EP - 878
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
SN - 0944-1174
IS - 11
ER -